A Phase 3 interventional study of iron isomaltoside 1000 and iron sulphate in Non-myeloid Malignancies and Chemotherapy Induced Anaemia, sponsored by Pharmacosmos A/S. Completed at 1 site in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-12-03.
Sponsored by Pharmacosmos A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to compare the efficacy and safety of intravenous iron therapy with oral iron therapy in patients with cancer and chemotherapy induced anaemia.
10,824 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 350 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Pharmacosmos A/S is the lead sponsor of 36 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Iron isomaltoside intravenously as bolus or infusion
Drug: iron isomaltoside 1000
oral iron sulphate twice a day
Drug: iron sulphate
intravenously as bolus or infusion, 500 mg or 1000mg up to full replacement dose
Also known as: Monofer
oral, 200 mg per day (100 mg bid),12 weeks
Also known as: Ferroduretter
Change in Hb Concentration
Time frame: Baseline week 4
Change in Hemoglobin From Baseline to Week 24
Time frame: 24 weeks
| Milestone | Iron Isomaltoside 1000 | Iron Sulphate |
|---|---|---|
| Started | 231 | 119 |
| Completed | 141 | 62 |
| Not completed | 90 | 57 |
| g/dL | Iron Isomaltoside 1000 | Iron Sulphate |
|---|---|---|
| Change in Hb Concentration | 0.48 (-4 to 4) | 0.44 (-2 to 4) |
| g/dL | Iron Isomaltoside 1000 | Iron Sulphate |
|---|---|---|
| Change in Hemoglobin From Baseline to Week 24 | 1.60 (-6.3 to 6.5) | 1.78 (-5.3 to 7.4) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Iron Isomaltoside 1000 | — | 32/229 (14%) | 173/229 (75.5%) |
| Iron Sulphate | — | 18/112 (16.1%) | 107/112 (95.5%) |
| Event | Iron Isomaltoside 1000 | Iron Sulphate |
|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 8/229 | 7/112 |
| AnaemiaBlood and lymphatic system disorders | 2/229 | 2/112 |
| Atrial fibrillationCardiac disorders | 3/229 | 1/112 |
| PancytopeniaBlood and lymphatic system disorders | 1/229 | 1/112 |
| Cardiac failureCardiac disorders | 1/229 | 1/112 |
| AscitesGastrointestinal disorders | 0/229 | 1/112 |
| AstheniaGeneral disorders | 1/229 | 1/112 |
| SepsisInfections and infestations | 0/229 | 1/112 |
| Unirary tract infectionInfections and infestations | 0/229 | 1/112 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/229 | 1/112 |
| Event | Iron Isomaltoside 1000 | Iron Sulphate |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 20/229 | 12/112 |
| LeukopeniaBlood and lymphatic system disorders | 12/229 | 10/112 |
| DiarrhoeaGastrointestinal disorders | 8/229 | 10/112 |
| Faeces discolouredGastrointestinal disorders | 1/229 | 9/112 |
| AlopeciaSkin and subcutaneous tissue disorders | 17/229 | 9/112 |
| AstheniaGeneral disorders | 18/229 | 7/112 |
| NauseaGastrointestinal disorders | 14/229 | 8/112 |
| VomitingGastrointestinal disorders | 16/229 | 7/112 |
| NeutropeniaBlood and lymphatic system disorders | 15/229 | 6/112 |
| ThrombocytopeniaBlood and lymphatic system disorders | 11/229 | 7/112 |
| Age, Categorical(Participants) | Iron Isomaltoside 1000 | Iron Sulphate | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 187 | 101 | 288 |
| >=65 years | 44 | 18 | 62 |
| Sex: Female, Male(Participants) | Iron Isomaltoside 1000 | Iron Sulphate | Total |
|---|---|---|---|
| Female | 151 | 90 | 241 |
| Male | 80 | 29 | 109 |
| Region of Enrollment(participants) | Iron Isomaltoside 1000 | Iron Sulphate | Total |
|---|---|---|---|
| India | 133 | 72 | 205 |
| Germany | 7 | 3 | 10 |
| Denmark | 3 | 1 | 4 |
| Spain | 2 | 0 | 2 |
| Poland | 40 | 16 | 56 |
| Russian Federation | 29 | 18 | 47 |
| Sweden | 5 | 3 | 8 |
| United States | 12 | 6 | 18 |
The record gives a start of Oct 2010, a primary completion of Apr 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2015, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iron isomaltoside 1000